Kurs
-3,20%
Likviditet
3,59 MNOK
Kalender
| Tid* | ||
| 2025-02-13 | 07:30 | Bokslutskommuniké 2024 |
| 2025-01-09 | N/A | Extra Bolagsstämma 2025 |
| 2024-11-06 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-21 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-07 | - | Kvartalsrapport 2024-Q1 |
| 2024-04-25 | - | X-dag ordinarie utdelning ULTI 0.00 NOK |
| 2024-04-24 | - | Årsstämma |
| 2024-02-14 | - | Bokslutskommuniké 2023 |
| 2023-11-08 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-22 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-10 | - | Kvartalsrapport 2023-Q1 |
| 2023-04-21 | - | X-dag ordinarie utdelning ULTI 0.00 NOK |
| 2023-04-20 | - | Årsstämma |
| 2023-02-16 | - | Bokslutskommuniké 2022 |
| 2022-11-10 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-19 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-12 | - | Kvartalsrapport 2022-Q1 |
| 2022-04-21 | - | X-dag ordinarie utdelning ULTI 0.00 NOK |
| 2022-04-20 | - | Årsstämma |
| 2022-02-17 | - | Bokslutskommuniké 2021 |
| 2021-11-11 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-20 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-11 | - | Kvartalsrapport 2021-Q1 |
| 2021-04-22 | - | X-dag ordinarie utdelning ULTI 0.00 NOK |
| 2021-04-21 | - | Årsstämma |
| 2021-02-17 | - | Bokslutskommuniké 2020 |
| 2020-11-12 | - | Kvartalsrapport 2020-Q3 |
| 2020-11-11 | - | Extra Bolagsstämma 2020 |
| 2020-08-21 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-14 | - | Kvartalsrapport 2020-Q1 |
| 2020-04-16 | - | X-dag ordinarie utdelning ULTI 0.00 NOK |
| 2020-04-15 | - | Årsstämma |
| 2020-02-14 | - | Bokslutskommuniké 2019 |
| 2019-11-14 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-21 | - | Kvartalsrapport 2019-Q2 |
Beskrivning
| Land | Norge |
|---|---|
| Lista | OB Match |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Oslo, 21 November 2022, Ultimovacs ASA (the "Company") refers to the announcement published on 16 November 2022 regarding the issuance of new shares in connection with the Company's employee incentive program.
The share capital increase related to the share issue of 130,700 new shares has been registered in the Norwegian Register of Business Enterprises, and the Company's new share capital is NOK 3,439,646.10, divided into 34,396,461 shares, each with a par value of NOK 0.10.
For further information, please contact:
Jónas Einarsson, Chairman of the Board of Directors of Ultimovacs ASA
Email: je@radforsk.no
Phone: +47 480 96 355
Carlos de Sousa, CEO
Email: carlos.desousa@ultimovacs.com
Phone: +47 908 92507
Hans Vassgård Eid, CFO
Email: hans.eid@ultimovacs.com
Phone: +47 482 48632